Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
My-Rept Tablet vs Capsule in Kidney Transplant
NCT01842269Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of CKD-4101 in kidney transplant rejection (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Rate of efficacy failure at 26 weeks. Started Jan 2013; status: completed.
02
Drugs
CKD-4101
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01842269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842269.